WO2016062270A1 - 呼吸***疾病用药用于制备抗癌医药组合物的用途 - Google Patents

呼吸***疾病用药用于制备抗癌医药组合物的用途 Download PDF

Info

Publication number
WO2016062270A1
WO2016062270A1 PCT/CN2015/092677 CN2015092677W WO2016062270A1 WO 2016062270 A1 WO2016062270 A1 WO 2016062270A1 CN 2015092677 W CN2015092677 W CN 2015092677W WO 2016062270 A1 WO2016062270 A1 WO 2016062270A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
drug
medication
use according
group
Prior art date
Application number
PCT/CN2015/092677
Other languages
English (en)
French (fr)
Inventor
陈丘泓
庄秀美
萧乃文
梁瑞岳
陈筱彤
Original Assignee
朗齐生物医学股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 朗齐生物医学股份有限公司 filed Critical 朗齐生物医学股份有限公司
Publication of WO2016062270A1 publication Critical patent/WO2016062270A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention is for the application of new indications for a variety of respiratory diseases, in particular, the use of the plurality of drugs for clinical trials and for inhibiting various cancers.
  • Cancer has long been the leading cause of death worldwide, and the number of cancer patients has increased year by year. Therefore, treating cancer has become an important issue.
  • the treatment of cancer can be divided into surgical treatment, radiation therapy, chemotherapy and target treatment.
  • cancer drug treatment is intended to prevent cancer cells from replicating and dividing to block the spread and spread of tumors.
  • chemotherapy chemotherapy or target treatment
  • cancer drug treatment is intended to prevent cancer cells from replicating and dividing to block the spread and spread of tumors.
  • chemotherapeutic drugs and target treatment hoping to kill cancer cells by different mechanisms to improve the therapeutic effect, but in fact, patients often react to the treatment of drugs Not good.
  • many cancer cells successively develop drug resistance, which greatly reduces the effectiveness of drug use, and ultimately leads to failure of cancer treatment.
  • Respiratory Diseases refers to a disease that is limited to the respiratory system. They are physiologically divided into two categories: obstructive pulmonary disease and restrictive lung disease. Anatomically, it can be divided into upper respiratory disease, lower respiratory disease, interstitial lung disease and vascular lung disease. Among them, Obstructive lung diseases include: Bronchitis, Bronchiolitis, Emphysema, Asthma, Chronic obstructive pulmonary disease (COPD) , Bronchiectasis, and Byssinosis. Restrictive lung diseases include: fibrosis, sarcoidosis (Sarcoidosis), Pleural effusion, Hypersensitivity pneumonitis, Asbestosis, Pleurisy.
  • Infectious lung diseases include: upper respiratory tract infections, lower respiratory tract infections or Pneumonia, and tuberculosis.
  • Interstitial lung diseases include: Idiopathic pulmonary fibrosis (IPF), Sarcoidosis, and Pneumoconiosis.
  • Vascular lung diseases include: pulmonary edema, pulmonary embolism, and pulmonary hypertension.
  • the present invention aims at the development of new indications for various drugs through clinical trials, and achieves the goal of new use of old drugs.
  • the experimental design results show that the respiratory disease medication has no or only minimal toxicity to normal cells, but whether the respiratory disease medication has a selective effect between normal cells and tumor cells remains to be further studied. Not all respiratory diseases can effectively inhibit tumor cells under the same conditions, and many problems need to be overcome.
  • Respiratory diseases can be divided into nine categories according to the use of drugs, including antitussives, antitussives, antiasthmatics, respiratory excitatory drugs, cold medications, acute bronchitis medications, chronic bronchitis medications, bronchial asthma medications and other kind.
  • the first category anti-infective respiratory disease medication
  • aminoglycoside respiratory disease medication is a class of respiratory diseases with amino sugar and aminocycloalcohol structure, mainly used in Gram-negative bacteria, Treatment of infections such as Pseudomonas aeruginosa.
  • the respiratory disease medication of the present invention includes Guaifenesin (Guaiphenesin), Dropropizine, and Oxeladin Citrate in this category.
  • the peony can be divided into three categories: 1 nausea and stimulating peony: the former such as fluorinated fluoride, potassium iodide, lignan glycerol ether, platycodon, etc. can stimulate the gastric mucosa after oral administration.
  • the former such as fluorinated fluoride, potassium iodide, lignan glycerol ether, platycodon, etc.
  • mucolytic agent such as Acetylcysteine, which decomposes the viscous components of sputum such as mucopolysaccharide and mucin, liquefied sputum, with reduced viscosity and easy coughing.
  • mucus regulators such as bromhexine and carboxymethylcysteine, mainly in the mucus and bronchial mucus producing cells, which promote the secretion of low-viscosity secretions, so that the rheology of the respiratory tract is restored to normal, sputum It is thinned by adhesion and easy to cough up.
  • the respiratory disease medication of the present invention is included in this category as Acetylcysteine, Erdosteine, Scopolamine hydrobromide, Moguisteine, Emetine, Oxeladin Citrate.
  • asthma drugs refers to a class of drugs that can act on different stages of asthma to relieve or prevent asthma attacks.
  • Commonly used antiasthmatic drugs can be divided into the following categories: 1 ⁇ adrenergic receptor agonist; 2 choline receptor antagonist; 3 phosphodiesterase inhibitor; 4 allergic medium release agent; 5 adrenocortical hormones; A triene receptor antagonist.
  • Asthma is characterized by bronchial smooth muscle spasm contraction, sputum stagnation and respiratory mucosal congestion and edema, so the airway obstruction, so that the air in and out is blocked, especially exhaled, showing wheezing difficulty.
  • Antiasthmatic drugs can relieve bronchial smooth muscle spasm through different mechanisms of action, allowing them to relax and expand, thus alleviating the symptoms of shortness of breath and difficulty breathing.
  • the respiratory disease medication of the present invention includes Dyphylline (Dilor), Aminophylline (Truphylline), Ipratropium bromide, Atropine, Montelukast Sodium, and Disodium Cromoglycate.
  • the fourth category acute bronchitis medication
  • acute bronchitis is caused by viral or bacterial pathogen infection caused by bronchial mucosal inflammation. It is a common and frequently-occurring disease in infants and young children. It is often secondary to upper respiratory tract infections and is often an early manifestation of pneumonia. This disease involves both the trachea and the bronchus, so the correct name should be acute tracheobronchitis.
  • the respiratory disease medication of the present invention is included in this category with Eprazinone.
  • the fifth category chronic bronchitis
  • chronic bronchitis is chronic non-specific inflammation of the trachea, bronchial mucosa and surrounding tissues due to infection or non-infective factors. Its pathological features are bronchial gland hyperplasia and increased mucus secretion. Clinically appear for more than two consecutive years, each holding Continued cough, cough or asthma for more than three months. Early symptoms are mild, mostly in the winter, relieved after warm spring; late inflammation is aggravated, symptoms persist for many years, regardless of season. Disease progression can be complicated by obstructive emphysema and pulmonary heart disease, which seriously affects labor and health.
  • the respiratory disease medication of the present invention includes Erdosteine and Eprazinone in this category.
  • bronchial asthma (Bronchial Asthma, referred to as asthma)
  • bronchial asthma is composed of a variety of cells (such as mast cells, eosinophils, T lymphocytes, neutrophils, airway epithelial cells, etc.) and Cellular components involved in airway chronic inflammatory diseases.
  • This chronic inflammation is associated with airway hyperresponsiveness, often with variable and variable reversible airflow limitation, and causes recurrent wheezing, shortness of breath, chest tightness, coughing, etc., often at night and/or early morning, Intensified, most patients can relieve themselves or after treatment. If bronchial asthma is not treated promptly, irreversible airway narrowing and airway remodeling may occur as the disease progresses.
  • the respiratory disease medication of the present invention includes Tranilast (SB 252218), Masititinib, Zileuton, Eprazinone, and Metaproterenol Sulfate in this category.
  • the present invention provides a use of a medicament for respiratory diseases for the preparation of an anticancer pharmaceutical composition, wherein the pharmaceutical composition is selected from the group consisting of an effective dose of a respiratory disease drug and a pharmaceutically acceptable salt.
  • the respiratory disease drug according to the present invention is selected from the group consisting of antitussive, antitussive, antiasthmatic, respiratory, excitatory, cold, acute bronchitis, chronic bronchitis, bronchial or other respiratory diseases. Medication.
  • the antitussive drug is a drug selected from the group consisting of one or more of Guaifenesin (Guaiphenesin), Dropropizine, and Oxeladin Citrate.
  • the medicinal agent is a drug selected from the group consisting of Acetylcysteine, Erdosteine, Scopolamine hydrobromide, Moguisteine, Emetine, Oxeladin Citrate.
  • the antiasthmatic drug is a drug selected from the group consisting of Dyphylline (Dilor), Aminophylline (Truphylline), Ipratropium bromide, Atropine, Montelukast Sodium, and Disodium Cromoglycate.
  • the acute bronchitis medication is Eprazinone.
  • the chronic bronchitis medication is a drug selected from the group consisting of one or more of Erdosteine and Eprazinone.
  • the bronchial asthma medication is a medicament selected from the group consisting of one or more of Tranilast (SB 252218), Masititinib, Zileuton, Eprazinone, and Metaproterenol Sulfate.
  • the cancer is one or more selected from the group consisting of lung cancer, intestinal cancer, colorectal cancer, prostate cancer, bladder cancer, cervical cancer, breast cancer, and blood cancer.
  • the effective dose concentration of the drug is from 20 mg/kg/day to 500 mg/kg/day.
  • Fig. 1 is a diagram showing the results of analyzing the cancer cell disease of the present invention for inhibiting cancer cells.
  • the cell lines of different cancer types were subcultured, and after counting the number of cells, 2 ⁇ 10 6 cells were placed in a culture dish, and then the culture medium in which the cell strain was cultured was added to a volume of 10 ml, and the culture was continued. 2-3 days. The cells were then counted and dispensed into 96-well plates where the number of cells per well was fixed at 3000 cells and the volume was 100 ul.
  • the original culture solution in the 96-well plate was aspirated, and a commercially available drug having a concentration of 10 ⁇ M and a volume of 100 ul was added to each well. After 72 hours, 100 ul of diluted WST-1 reagent was added to each well, and the dilution ratio was the culture solution and The volume ratio of the WST-1 stock solution is 9:1. Finally, the total volume of each well plate is 200 ul. Then, the 96-well plate is placed at 37 ° C for 30-90 minutes, using an elisa reader (ELISA) on the OD450. The absorbance values were detected and the survival rate of each cancer cell line was calculated.
  • ELISA elisa reader
  • Respiratory disease medication is used to inhibit cancer cell analysis results
  • Respiratory diseases are divided into nine categories, namely anti-infectives, antitussives, antitussives, antiasthmatics, respiratory excitatory drugs, cold medications, acute bronchitis medications, chronic bronchitis medications, bronchial asthma medications The effect of cancer cell growth.
  • the relative anti-respiratory disease drug molecules have different inhibitory effects on various cancer cells (Fig. 1).
  • the drug for the respiratory disease drug Masititinib (AB1010) (Masatinib AB1010) was confirmed.
  • Masititinib (AB1010) has inhibitory effects on lung cancer, gastric cancer, rectal cancer, and skin cancer;
  • Ivacaftor (VX-770) has lung cancer, gastric cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, and blood cancer.
  • Tranilast SB 252218
  • Dyphylline Dilor
  • Acetylcysteine has inhibitory effect on gastric cancer, bladder cancer and breast cancer
  • Aminophylline Trine
  • Ipratropium bromide has inhibitory effect on gastric cancer
  • Guaifenesin (Guaiphenesin) has inhibitory effect on skin cancer and breast cancer
  • Erdosteine has inhibitory effect on gastric cancer
  • Disodium Cromoglycate has lung cancer, gastric cancer, colon cancer, prostate cancer
  • Chlormezanone Trancopal
  • Urapidil HCl has inhibitory effect on lung cancer, gastric cancer and rectal cancer
  • Lovastatin Mevacor
  • Emetine has inhibitory effect on lung cancer, gastric cancer, liver cancer, colon cancer, skin cancer, prostate cancer, bladder cancer, breast cancer, blood cancer; Metaproterenol Sulfate has inhibitory effect on liver cancer; Oxeladin Citrate on lung cancer, stomach cancer, colon cancer, skin Cancer, breast cancer has an inhibitory effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种呼吸***疾病用药用于制备抗癌医药组合物的用途。所述呼吸***疾病用药是选自由镇咳用药、祛痰用药、平喘用药、呼吸兴奋用药、感冒用药、急性支气管炎用药、慢性支气管炎用药、支气管哮喘用药类及其他呼吸***疾病用药。

Description

呼吸***疾病用药用于制备抗癌医药组合物的用途 技术领域
本发明为多种呼吸***疾病用药的新适应症的应用，尤其该多种药物为通过临床实验且具有抑制多种癌症的用途。
背景技术
癌症长期高居全球死因之首，且罹患癌症人数更是逐年攀升，因此治疗癌症俨然成为重要的课题。癌症的治疗可区分为手术治疗、放射线治疗、化学治疗及标靶治疗。
一般来说，癌症药物治疗无论是化学治疗或标靶治疗，目的多是让癌细胞无法复制、***，来阻断肿瘤的蔓延扩张。在临床治疗选择上，通常会结合一到数种化疗药物以及标靶治疗，希望能藉由不同机制来杀死癌细胞以提高治疗效果，但事实上，还是常遇到患者对于治疗药物的反应不佳。进一步，许多癌细胞相继产生抗药性，使药物的使用成效大幅降低，最终导致癌症治疗失败。
呼吸***疾病(Respiratory Diseases)。是指局限于呼吸***的疾病。从生理上分为两类：阻塞性肺病和限制性肺疾病。从解剖学上可分为：上呼吸道疾病、下呼吸道疾病、肺间质疾病和血管性肺病。其中，阻塞性肺病(Obstructive lung diseases)包含:支气管炎(Bronchitis)、小支气管炎(Bronchiolitis)、肺气肿(Emphysema)、哮喘(Asthma)、慢性阻塞性肺病[Chronic obstructive pulmonary disease(COPD)]、支气管扩张(Bronchiectasis)、棉尘症(Byssinosis)。而限制性肺疾病(Restrictive lung diseases)包含:肺纤维化(Fibrosis)、结节病 (Sarcoidosis)、胸腔积液(Pleural effusion)、过敏性肺炎(Hypersensitivity pneumonitis)、石棉肺(Asbestosis)、胸膜炎(Pleurisy)。感染性肺病(Infectious lung diseases)包含:上呼吸道感染(Upper respiratory tract infections)、下呼吸道感染(Lower respiratory tract infections or Pneumonia)、肺结核(Tuberculosis)。肺间质疾病(Interstitial lung diseases)包含:特发性肺纤维化(Idiopathic pulmonary fibrosis,IPF)、结节病(Sarcoidosis)、尘肺病(Pneumoconiosis)。血管性肺病(Vascular lung diseases)包含:肺水肿(Pulmonary edema)、肺栓塞(Pulmonary embolism)、肺动脉高压(Pulmonary hypertension)。
发明人依据长年的研究经验，人类的癌症细胞常常有与正常细胞具有不同的表现性状，型态上的差异或是作用机转的变化或许也有可能被视为一种外来的侵入者，而每一种癌症细胞所在的位置不同，变异的状态又与所处的环境有关，因此，第一个提出使用呼吸***疾病用药抑制癌症细胞的发明概念并且进行实验。
相对的，在这些已经使用数十年呼吸***疾病用药，是早已被FDA所认可的用药，具有大量药物机转及人体研究成果数据，因此，若应用在癌症方面，这项新发展会更省时、减少成本，也能和其他治疗方式结合来提高效果。目前尚未有任何研究针对本发明所使用的药物，进行癌症治疗研究。
尽管如此，药物开发依然是重要的医学议题，必须经过繁复的临床前试验才能进入临床试验，根据统计，平均每一万个新药约只有五个能够进入第一期临床试验。此外，除了药物本身是否能大量制造的难题外，还需克服药物安全性、病人筛选、试用剂量等问题，即便药物已经通过FDA的核准并上市，亦有可能因上市后于人体发现不良反应而强制下架回收，由此可见药物开发具有一定的 困难程度。
发明内容
为解决上述的问题，本发明针对通过临床实验的多种药物进行新适应症的研发，而达到老药新用的目标。
经过实验设计结果显示呼吸***疾病用药对正常细胞没有或仅有微小的毒性，但至于呼吸***疾病用药在正常细胞与肿瘤细胞之间是否具有选择性的影响，还待更多的研究厘清，而且并非所有的呼吸***疾病用药在相同的条件下均能有效的抑制肿瘤细胞，需要有许多的问题进行克服。
名词定义
呼吸***疾病用药依据药物的用途可以分为九大类，包含镇咳用药、祛痰用药、平喘用药、呼吸兴奋用药、感冒用药、急性支气管炎用药、慢性支气管炎用药、支气管哮喘用药类与其他类。
第一大类:抗感染用的呼吸***疾病用药，氨基糖苷类呼吸***疾病用药是具有氨基糖与氨基环醇结构的一类呼吸***疾病用药，在临床主要用于对革兰氏阴性菌、绿脓杆菌等感染的治疗。本发明中的呼吸***疾病用药包含在本类别的有Guaifenesin(Guaiphenesin)、Dropropizine、Oxeladin Citrate。
第二大类:祛痰用药，痰是呼吸道炎症的产物，其可刺激呼吸道粘膜而引起咳嗽，并可能加重感染的程度。祛痰用药可稀释痰液或液化粘痰，使之易于咳出。按其作用方式可将祛痰药分为三类：①恶心性祛痰药和刺激性祛痰药：前者如氯化氟、碘化钾、木酚甘油醚、桔梗、等口服后可刺激胃粘膜，引起轻微的恶心反映，反射性地促进呼吸道腺体分泌增加，使痰液稀释，易于咳出。后者是一些挥发性物质，如桉叶油、安息香酊等，将之加入沸水中，其蒸气亦可刺激呼吸道粘膜，增加腺体分泌，使痰液变稀，易于咳出。②黏液溶解剂：如 乙酰半胱氨酸，其可分解痰液的粘性成分如黏多糖和黏蛋白，液化痰液，黏滞性降低而易于咳出。③黏液调节剂：如溴己新和羧甲半胱氨酸，主要作用于气管、支气管的黏液产生细胞，促其分泌粘滞性低的分泌物，使呼吸道分泌的流变性恢复正常，痰液由黏变稀，易于咳出。本发明中的呼吸***疾病用药包含在本类别的有Acetylcysteine、Erdosteine、Scopolamine hydrobromide、Moguisteine、Emetine、Oxeladin Citrate。
第三大类:平喘药，是指能作用于哮喘发病的不同环节，以缓解或预防哮喘发作的一类药物。常用平喘药可分为以下几类：①β肾上腺素受体激动剂；②胆碱受体拮抗剂；③磷酸二酯酶抑制剂；④过敏介质阻释剂；⑤肾上腺皮质激素类；⑥白三烯受体拮抗剂。哮喘的特点为支气管平滑肌痉挛性收缩，痰液积滞和呼吸道黏膜充血水肿，于是气道阻塞，使空气出入受到阻碍，以呼气尤为严重，呈现喘息性吸入困难。平喘药能通过不同作用机制而缓解支气管平滑肌痉挛，使其松弛和扩张，因而可以缓解气急，呼吸困难的症状。本发明中的呼吸***疾病用药包含在本类别的有Dyphylline(Dilor)、Aminophylline(Truphylline)、Ipratropium bromide、Atropine、Montelukast Sodium、Disodium Cromoglycate。
第四大类:急性支气管炎用药，急性支气管炎是病毒或细菌等病原体感染所致的支气管黏膜炎症。是婴幼儿时期的常见病、多发病，往往继发于上呼吸道感染之后，也常为肺炎的早期表现。本病多同时累及气管、支气管，故正确命名应为急性气管支气管炎。本发明中的呼吸***疾病用药包含在本类别的有Eprazinone。
第五大类:慢性支气管炎用药，慢性支气管炎(chronic bronchitis)是由于感染或非感染因素引起气管、支气管黏膜及其周围组织的慢性非特异性炎症。其病理特点是支气管腺体增生、黏液分泌增多。临床出现有连续两年以上，每持 续三个月以上的咳嗽、咳痰或气喘等症状。早期症状轻微，多在冬季发作，春暖后缓解；晚期炎症加重，症状长年存在，不分季节。疾病进展又可并发阻塞性肺气肿、肺源性心脏病，严重影响劳动力和健康。本发明中的呼吸***疾病用药包含在本类别的有Erdosteine、Eprazinone。
第六大类:支气管哮喘用药，支气管哮喘(Bronchial Asthma，简称哮喘)，是由多种细胞(比如肥大细胞、嗜酸性粒细胞、T淋巴细胞、中性粒细胞、气道上皮细胞等)和细胞组分参与的气道慢性炎症性疾病。这种慢性炎症与气道高反应性相关，通常出现广泛多变的可逆性气流受限，并引起反复发作性的喘息、气急、胸闷、咳嗽等症状，常在夜间和(或)清晨发作、加剧，多数患者可自行缓解或经过治疗缓解。支气管哮喘如诊治不及时，随着病程的延长可发生气道不可逆性缩窄和气道重塑。而当哮喘得到控制后，多数患者很少出现哮喘发作，严重哮喘发作则更少见。来自全球哮喘负担的数据表明，尽管从患者和社会的角度来看，控制哮喘的花费似乎很高，但不正确的治疗可导致哮喘反复发作，治疗费用将会更高。因此，合理的防治至关重要。为此，世界各国的哮喘防治专家共同起草，并不断更新了全球哮喘防治倡议(Global Initiative For Asthma，GINA)。本发明中的呼吸***疾病用药包含在本类别的有Tranilast(SB 252218)、Masitinib、Zileuton、Eprazinone、Metaproterenol Sulfate。
本发明提供一种呼吸***疾病用药用于制备抗癌医药组合物的用途，其中所述医药组合物是选自由有效剂量的呼吸***疾病用药及医药上可接受的盐类所组成。
本发明所述的呼吸***疾病用药选自、镇咳用药、祛痰用药、平喘用药、呼吸兴奋用药、感冒用药、急性支气管炎用药、慢性支气管炎用药、支气管哮喘用药类或其他呼吸***疾病用药。
本发明一实施例中，其中所述镇咳用药是选自由Guaifenesin(Guaiphenesin)、Dropropizine、Oxeladin Citrate中的一种或多种所组成的药物。
本发明一实施例中，其中所述祛痰用药是选自由Acetylcysteine、Erdosteine、Scopolamine hydrobromide、Moguisteine、Emetine、Oxeladin Citrate中的一种或多种所组成的药物。
本发明一实施例中，其中所述平喘用药是选自由Dyphylline(Dilor)、Aminophylline(Truphylline)、Ipratropium bromide、Atropine、Montelukast Sodium、Disodium Cromoglycate中的一种或多种所组成的药物。
本发明一实施例中，其中所述急性支气管炎用药是Eprazinone。
本发明一实施例中，其中所述慢性支气管炎用药是选自由Erdosteine、Eprazinone中的一种或多种所组成的药物。
本发明一实施例中，其中所述支气管哮喘用药是选自由Tranilast(SB 252218)、Masitinib、Zileuton、Eprazinone、Metaproterenol Sulfate中的一种或多种所组成的药物。
本发明一实施例中，其中所述癌症是选自由肺癌、肠道癌、大肠直肠癌、***癌、膀胱癌、子***、乳癌、血癌中的一种或多种。
本发明一实施例中，其中所述药物的有效剂量浓度为20mg/kg/天～500mg/kg/天。
现今癌症药物费用动辄上万至数百万元，若未来更进一步证实呼吸***疾病用药对肿瘤的疗效，对于无法负担昂贵治疗的患者们，这些便宜而历史悠久的药物，会是带来健康的新希望。
附图说明
图1为本发明呼吸***疾病用药应用于抑制癌细胞分析结果。
具体实施方式
建立细胞株
参照表一，将不同癌症类型的细胞株进行继代培养，计算细胞数目后，将2×106细胞数置入培养皿，然后加入培养该细胞株的培养液补至体积为10ml，继续培养2-3天。之后将细胞计数，并分装至96孔盘，其中每孔的细胞数目固定为3000个细胞，且体积为100ul。
表一、细胞株及其培养所用的培养液
Figure PCTCN2015092677-appb-000001
细胞存活分析方法
将96孔盘中原有的培养液吸掉，每孔加入浓度10μM、体积100ul的市售药物，放置72小时后，每孔再加入100ul已稀释的WST-1试剂，该稀释比例为培养液与WST-1原液的体积比为9：1，最后每个孔盘的总体积为200ul，然后将96孔盘放置于37℃，30～90分钟，利用elisa reader(酶联免疫检测仪)于OD450侦测吸光值，并计算各癌症细胞株的存活率。
呼吸***疾病用药应用于抑制癌细胞分析结果
呼吸***疾病用药分为九大类，分别为抗感染用药、镇咳用药、祛痰用药、平喘用药、呼吸兴奋用药、感冒用药、急性支气管炎用药、慢性支气管炎用药、支气管哮喘用药类抑制癌细胞生长的效果。
实验结果明显的显示有许多的呼吸***疾病用药并无法有效的抑制癌症的细胞的生长(表二)。
表二、对癌症细胞株无抑制效果的呼吸***疾病用药
药 抑制癌症细胞株数量
Zileuton 0
Scopolamine hydrobromide 0
Montelukast Sodium 0
而相对的各种的呼吸***疾病用药分子对于各种癌症细胞的抑制效果也不尽相同(图一)，经过发明人实验结果，证实呼吸***疾病用药药物Masitinib(AB1010)(马赛替尼AB1010)、Ivacaftor(VX-770)、Tranilast(SB 252218)(曲尼斯特、肉桂氨茴酸)、Dyphylline(Dilor)(二羟丙茶碱(喘定))、Acetylcysteine(乙酰半胱氨酸)、Aminophylline(Truphylline)(茶碱(氨茶碱制剂))、Ipratropium bromide(异丙托溴铵)、Guaifenesin(Guaiphenesin)(愈创木酚甘油醚(愈创木酚甘油醚))、Erdosteine(厄多半胱、厄多司坦)、Disodium Cromoglycate(色甘酸钠)、Chlormezanone(Trancopal)(氯美扎酮)、Urapidil HCl(盐酸乌拉地尔)、Lovastatin(Mevacor)(洛伐他汀(美降脂))、Atropine(阿托品)、Gabapentin(Neurontin)(加巴喷丁(Neurontin))、Moguisteine(莫吉司坦)、Vitamin C(Ascorbic acid)(维生素C(抗坏血酸))、Eprazinone 2HCl (依普拉酮盐酸盐)、Dropropizine(羟丙哌嗪)、Benzocaine(苯佐卡因)、Emetine(吐根素、依米丁)、Metaproterenol Sulfate(硫酸奥西那林、硫酸间羟异丙肾上腺素)、Oxeladin Citrate(沃克拉丁柠檬酸、枸橼酸奥昔拉定)等药物对于不同的癌症细胞有明显的抑制效果。(表三)
Figure PCTCN2015092677-appb-000002
Figure PCTCN2015092677-appb-000003
如表三所示，Masitinib(AB1010)对肺癌,胃癌,直肠癌,皮肤癌有抑制效果；Ivacaftor(VX-770)对肺癌,胃癌,,结肠癌,皮肤癌,***癌,膀胱癌,血癌有抑制效果；Tranilast(SB 252218)对肺癌,胃癌,皮肤癌,***癌有抑制效果；Dyphylline(Dilor)对肺癌,胃癌,膀胱癌有抑制效果；Acetylcysteine对胃癌,膀胱癌,乳癌有抑制效果；Aminophylline(Truphylline)对胃癌有抑制效果；Ipratropium bromide对胃癌有抑制效果；Guaifenesin(Guaiphenesin)对皮肤癌,乳癌有抑制效果；Erdosteine对胃癌有抑制效果；Disodium Cromoglycate对肺癌,胃癌,,结肠癌,***癌,乳癌有抑制效果；Chlormezanone(Trancopal)对肺癌,胃癌,直肠癌有抑制效果；Urapidil HCl对肺癌,胃癌,直肠癌有抑制效果；Lovastatin(Mevacor)对肺癌,胃癌,结肠癌,皮肤癌,***癌,乳癌有抑制效果；Atropine对胃癌,皮肤癌,膀胱癌有抑制效果；Gabapentin(Neurontin)对胃癌有抑制效果；Moguisteine对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,***癌,膀胱癌有抑制效果；Vitamin C(Ascorbic acid)对肺癌,胃癌,肝癌,直肠癌,结肠癌,皮肤癌,膀胱癌,乳癌有抑制效果；Eprazinone 2HCl对肺癌,胃癌,直肠癌,皮肤癌,乳癌有抑制效果；Dropropizine对肺癌,胃癌,直肠癌,皮肤癌,乳癌有抑制效果；Benzocaine对直肠癌,皮肤癌,乳癌有抑制效果；Emetine对肺癌,胃癌,肝癌,结肠癌,皮肤癌,***癌,膀胱癌,乳癌,血癌有抑制效果；Metaproterenol Sulfate对肝癌有抑制效果；Oxeladin Citrate对肺癌,胃癌,结肠癌,皮肤癌,乳癌有抑制效果。
重复性实验
依据表三所示结果，针对对癌症细胞株有效的药物进行重复性实验，其结果如表四所示。
表四、具有抑制癌症细胞株的呼吸***疾病用药
Figure PCTCN2015092677-appb-000004

Claims (9)

  1. 一种呼吸***疾病用药用于制备抗癌医药组合物的用途，其特征是，所述医药组合物是选自由有效剂量的呼吸***疾病用药及药学上可接受的盐类所组成。
  2. 如权利要求1所述的用途，其特征是，所述呼吸***疾病用药是选自由镇咳用药、祛痰用药、平喘用药、呼吸兴奋用药、感冒用药、急性支气管炎用药、慢性支气管炎用药、支气管哮喘用药类及其他呼吸***疾病用药。
  3. 如权利要求2所述的用途，其特征是，所述镇咳用药是选自由Guaifenesin (Guaiphenesin)、Dropropizine、Oxeladin Citrate中的一种或多种所组成的药物。
  4. 如权利要求2所述的用途，其特征是，所述祛痰用药是选自由Acetylcysteine、Erdosteine、Scopolamine hydrobromide、Moguisteine、Emetine、Oxeladin Citrate中的一种或多种所组成的药物。
  5. 如权利要求2所述的用途，其特征是，所述平喘用药是选自由Dyphylline (Dilor)、Aminophylline(Truphylline)、Ipratropium bromide、Atropine、Montelukast Sodium、Disodium Cromoglycate中的一种或多种所组成的药物。
  6. 如权利要求2所述的用途，其特征是，所述急性支气管炎用药为Eprazinone药物。
  7. 如权利要求2所述的用途，其特征是，所述慢性支气管炎用药是选自由Erdosteine、Eprazinone中的一种或两种。
  8. 如权利要求2所述的用途，其特征是，所述支气管哮喘用药类是选自由 Tranilast(SB 252218)、Masitinib、Zileuton、Eprazinone、Metaproterenol Sulfate中的一种或多种所组成的药物。
  9. 如权利要求1所述的用途，其特征是，所述癌症为肺癌、肠道癌、大肠直肠癌、***癌、膀胱癌、子***、乳癌、血癌中的一种或多种。
PCT/CN2015/092677 2014-10-24 2015-10-23 呼吸***疾病用药用于制备抗癌医药组合物的用途 WO2016062270A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068298P 2014-10-24 2014-10-24
US62/068,298 2014-10-24

Publications (1)

Publication Number Publication Date
WO2016062270A1 true WO2016062270A1 (zh) 2016-04-28

Family

ID=55760314

Family Applications (21)

Application Number Title Priority Date Filing Date
PCT/CN2015/092782 WO2016062291A1 (zh) 2014-10-24 2015-10-23 千忧解药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092702 WO2016062274A1 (zh) 2014-10-24 2015-10-23 消化***疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092780 WO2016062289A1 (zh) 2014-10-24 2015-10-23 帕罗西汀药物用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092761 WO2016062279A1 (zh) 2014-10-24 2015-10-23 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途
PCT/CN2015/092617 WO2016062265A1 (zh) 2014-10-24 2015-10-23 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092632 WO2016062266A1 (zh) 2014-10-24 2015-10-23 氨氯地平在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092779 WO2016062288A1 (zh) 2014-10-24 2015-10-23 代谢性疾病药物用于制备抑制癌症的医药组合物的用途
PCT/CN2015/092771 WO2016062283A1 (zh) 2014-10-24 2015-10-23 抗发炎用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092714 WO2016062275A1 (zh) 2014-10-24 2015-10-23 阿折地平在制备治疗癌症的医药组合物中的用途
PCT/CN2015/092768 WO2016062281A1 (zh) 2014-10-24 2015-10-23 心血管疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092781 WO2016062290A1 (zh) 2014-10-24 2015-10-23 氨苯蝶啶药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092753 WO2016062278A1 (zh) 2014-10-24 2015-10-23 内分泌疾病用药在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092746 WO2016062277A1 (zh) 2014-10-24 2015-10-23 驱虫药用于制备抗癌医药组合物中的应用
PCT/CN2015/092777 WO2016062287A1 (zh) 2014-10-24 2015-10-23 山喜多药物在用于制备抑制癌症的医药组合物中的用途
PCT/CN2015/092775 WO2016062285A1 (zh) 2014-10-24 2015-10-23 神经***疾病用药在制备抗癌医药组合物中的应用
PCT/CN2015/092677 WO2016062270A1 (zh) 2014-10-24 2015-10-23 呼吸***疾病用药用于制备抗癌医药组合物的用途
PCT/CN2015/092697 WO2016062272A1 (zh) 2014-10-24 2015-10-23 免疫疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092776 WO2016062286A1 (zh) 2014-10-24 2015-10-23 脱克钙药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092666 WO2016062269A1 (zh) 2014-10-24 2015-10-23 阿那格雷在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092653 WO2016062267A1 (zh) 2014-10-24 2015-10-23 奈必洛尔在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092686 WO2016062271A1 (zh) 2014-10-24 2015-10-23 抗生素药物用于制备治疗癌症的医药组合物的用途

Family Applications Before (15)

Application Number Title Priority Date Filing Date
PCT/CN2015/092782 WO2016062291A1 (zh) 2014-10-24 2015-10-23 千忧解药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092702 WO2016062274A1 (zh) 2014-10-24 2015-10-23 消化***疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092780 WO2016062289A1 (zh) 2014-10-24 2015-10-23 帕罗西汀药物用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092761 WO2016062279A1 (zh) 2014-10-24 2015-10-23 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途
PCT/CN2015/092617 WO2016062265A1 (zh) 2014-10-24 2015-10-23 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092632 WO2016062266A1 (zh) 2014-10-24 2015-10-23 氨氯地平在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092779 WO2016062288A1 (zh) 2014-10-24 2015-10-23 代谢性疾病药物用于制备抑制癌症的医药组合物的用途
PCT/CN2015/092771 WO2016062283A1 (zh) 2014-10-24 2015-10-23 抗发炎用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092714 WO2016062275A1 (zh) 2014-10-24 2015-10-23 阿折地平在制备治疗癌症的医药组合物中的用途
PCT/CN2015/092768 WO2016062281A1 (zh) 2014-10-24 2015-10-23 心血管疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092781 WO2016062290A1 (zh) 2014-10-24 2015-10-23 氨苯蝶啶药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092753 WO2016062278A1 (zh) 2014-10-24 2015-10-23 内分泌疾病用药在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092746 WO2016062277A1 (zh) 2014-10-24 2015-10-23 驱虫药用于制备抗癌医药组合物中的应用
PCT/CN2015/092777 WO2016062287A1 (zh) 2014-10-24 2015-10-23 山喜多药物在用于制备抑制癌症的医药组合物中的用途
PCT/CN2015/092775 WO2016062285A1 (zh) 2014-10-24 2015-10-23 神经***疾病用药在制备抗癌医药组合物中的应用

Family Applications After (5)

Application Number Title Priority Date Filing Date
PCT/CN2015/092697 WO2016062272A1 (zh) 2014-10-24 2015-10-23 免疫疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092776 WO2016062286A1 (zh) 2014-10-24 2015-10-23 脱克钙药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092666 WO2016062269A1 (zh) 2014-10-24 2015-10-23 阿那格雷在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092653 WO2016062267A1 (zh) 2014-10-24 2015-10-23 奈必洛尔在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092686 WO2016062271A1 (zh) 2014-10-24 2015-10-23 抗生素药物用于制备治疗癌症的医药组合物的用途

Country Status (9)

Country Link
US (7) US10098852B2 (zh)
EP (3) EP3222278B1 (zh)
JP (1) JP6539345B2 (zh)
KR (1) KR102490334B1 (zh)
CN (3) CN106999470A (zh)
AU (2) AU2015335391B2 (zh)
ES (1) ES2954860T3 (zh)
TW (21) TW201615194A (zh)
WO (21) WO2016062291A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
KR101933805B1 (ko) 2017-10-17 2018-12-28 성균관대학교산학협력단 옥셀라딘시트레이트를 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학적 조성물

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015335391B2 (en) * 2014-10-24 2018-06-21 Launx Biomedical Co., Ltd. Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer
AU2015370666B2 (en) 2014-12-22 2020-09-03 Arovella Therapeutics Limited Prevention and treatment of metastatic disease in thrombocytotic cancer patients
WO2017116049A1 (ko) * 2015-12-31 2017-07-06 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 치료 및 전이 억제용 약학적 조성물
EP3241562A1 (en) * 2016-05-02 2017-11-08 Fundació Institut Mar d'Investigacio Medica Zonisamide for use in the treatment of breast cancer
CN106074474A (zh) * 2016-06-15 2016-11-09 中南大学湘雅医院 羟苄丝肼及其在药学上可接受的盐在制备抗肿瘤药物方面的应用
WO2018072135A1 (zh) 2016-10-19 2018-04-26 微菌方舟生物科技股份有限公司 二氢吡啶类钙拮抗剂用于治疗癌症的用途
CN108066345A (zh) * 2016-11-14 2018-05-25 武汉华杰世纪生物医药有限公司 一种具有抗肿瘤作用的化合物
MX2019007391A (es) 2016-12-20 2019-08-16 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US20200179404A1 (en) * 2017-06-09 2020-06-11 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
WO2019008516A2 (en) * 2017-07-03 2019-01-10 Menri Group Ltd. TREATMENT OF CANCER WITH DIHYDROPYRIDINES
JP2019064976A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
CN108186652A (zh) * 2017-12-28 2018-06-22 深圳大学 缝隙连接细胞间通迅抑制剂甘珀酸在制备预防和治疗肝细胞癌药物中的应用
WO2019152475A1 (en) 2018-01-30 2019-08-08 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
WO2019204764A1 (en) * 2018-04-19 2019-10-24 Washington University Compositions and methods of use thereof for treatment of proteinopathies
WO2019243452A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
FR3090084B1 (fr) 2018-12-18 2023-10-13 Securengy Projectile pour armes à feu ou air comprimé pour emport liquide ou pulvérulent.
US20220072089A1 (en) * 2018-12-19 2022-03-10 University Of Vermont And State Agricultural College Cancer therapeutic compositions and methods
CN113924090A (zh) * 2019-04-04 2022-01-11 大邱庆北尖端医疗产业振兴财团 用于预防或治疗癌症的包含曲美布汀或其药学上可接受的盐作为活性成分的药物组合物
US20220202771A1 (en) * 2019-04-05 2022-06-30 University Of North Texas Health Science Center At Fort Worth Antidepressants for the Treatment or Prevention of Memory Loss and/or Cognitive Decline or Dysfunction in Aging
US20220146492A1 (en) * 2019-04-11 2022-05-12 Ian Basil Shine Cell membrane permeability restoring therapy
CN110179803A (zh) * 2019-05-31 2019-08-30 天津科技大学 一种噻吨溴类化合物的应用
CN110742890A (zh) * 2019-10-24 2020-02-04 暨南大学 洛美利嗪在制备抗结肠癌药物中的应用
CN110840887A (zh) * 2019-11-18 2020-02-28 杭州彗搏科技有限公司 三氯苯达唑在制备治疗乳腺癌的药物中的应用
CN110876800B (zh) * 2019-11-18 2023-06-27 中南大学 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN111067899B (zh) * 2020-01-08 2021-03-05 温州医科大学 一种抗疟药物磷酸伯氨喹在制备治疗白血病药物上的应用
US11304969B2 (en) * 2020-01-24 2022-04-19 The Florida International Univeristy Board Of Trustees Treatments of prostate cancer
CN111973593A (zh) * 2020-05-09 2020-11-24 深圳市罗湖区人民医院 硝唑尼特及其药学上可接受的盐在制备治疗膀胱癌药物中的用途
CN111557941A (zh) * 2020-06-15 2020-08-21 浙江大学 Plod2的小分子抑制剂米诺地尔在肿瘤治疗中的应用
CN111848717A (zh) * 2020-08-07 2020-10-30 四川大学 靶向调控线粒体能量代谢的化合物及其应用和药物
TW202214245A (zh) * 2020-08-10 2022-04-16 國立彰化師範大學 雙非癌藥物用於製備治療癌症之醫藥組合物的用途
CN112274525B (zh) * 2020-12-04 2022-04-08 遵义医科大学 一种化疗药物组合物及其应用
CN112336725A (zh) * 2020-12-11 2021-02-09 吴照球 甲氧苄啶的医药新用途
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
CN112569215A (zh) * 2020-12-30 2021-03-30 东莞市人民医院 度米芬在制备防治结直肠癌的药物中的应用
EP4108244A1 (en) * 2021-06-25 2022-12-28 Universität Regensburg Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
CN113663071B (zh) * 2021-06-28 2022-12-30 四川大学 Fbxl2激活剂在制备治疗egfr驱动的肺癌的药物中的用途
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
WO2023035200A1 (zh) * 2021-09-09 2023-03-16 中国福利会国际和平妇幼保健院 五氟利多在制备治疗子宫内膜癌的药物中的应用
CN115887455B (zh) * 2022-08-04 2024-04-05 北京大学人民医院 钙离子通道阻滞剂阿折地平在制备治疗子宫内膜癌的药物中的应用
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024311A1 (en) * 2005-08-24 2007-03-01 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
WO2008085875A2 (en) * 2007-01-05 2008-07-17 Cornerstone Therapeutics Inc. R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma)
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
WO2012100248A1 (en) * 2011-01-23 2012-07-26 The University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
WO2014053650A1 (en) * 2012-10-04 2014-04-10 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721335B1 (en) * 1993-10-01 2005-08-31 Roche Palo Alto LLC Mycophenolate mofetil high dose oral suspensions
KR100264348B1 (ko) * 1994-12-28 2000-08-16 디르크 반테 항-죽종형성제로서 네비볼롤을 함유하는 조성물
AU746887B2 (en) * 1998-09-15 2002-05-02 Eli Lilly And Company Treatment of persistent pain
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
WO2002004406A2 (en) * 2000-07-07 2002-01-17 Trustees Of Tufts College 9-substituted minocycline compounds
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN1878556A (zh) * 2003-09-18 2006-12-13 康宾纳特克斯公司 ***的联合药物
KR20060124607A (ko) * 2003-11-06 2006-12-05 셀진 코포레이션 암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물
EP1753425A4 (en) * 2004-05-12 2009-08-05 Biorunx Co Ltd THERAPEUTIC AGENT COMPRISING A NICOTINIC ACID OR DERIVATIVES AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER
DK1753713T3 (en) * 2004-05-21 2016-11-28 Harvard College SYNTHESIS OF TETRACYCLINES AND ANALOGS THEREOF
CN1279980C (zh) * 2004-10-14 2006-10-18 孔庆忠 一种抗实体肿瘤药物组合物
JP2006298781A (ja) * 2005-04-15 2006-11-02 Geno Membrane:Kk エストロン３硫酸トランスポーター活性阻害剤
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CN101223149A (zh) * 2005-07-05 2008-07-16 特瓦制药工业有限公司 制备缬沙坦的方法
ES2661169T3 (es) * 2005-07-28 2018-03-27 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Compuestos de monofenol, bencenodiol, o sulfhidrilo para uso en el tratamiento de melanomas
AU2007230724B2 (en) * 2006-03-23 2014-01-30 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
CN101099724A (zh) * 2006-07-07 2008-01-09 上海复旦复华药业有限公司 一种微粉化来曲唑及其组合物
CN101103976A (zh) * 2006-07-14 2008-01-16 海南盛科生命科学研究院 一种含阿那曲唑的口服药物组合物及其制备工艺
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
CA2691196C (en) * 2007-06-21 2016-05-24 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
WO2009025854A1 (en) * 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
CN100563645C (zh) * 2007-12-06 2009-12-02 济南帅华医药科技有限公司 一种治疗实体肿瘤的蓓萨罗丁缓释植入剂
WO2009126274A2 (en) * 2008-04-08 2009-10-15 New York University School Of Medicine Methods and compositions for the treatment of cancers, such as melanomas and gliomas
CN101569624A (zh) * 2008-04-29 2009-11-04 石药集团中奇制药技术（石家庄）有限公司 氨氯地平在制备治疗细胞增生性疾病药物中的用途
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
CN101991553B (zh) * 2009-08-21 2015-02-25 北京以岭生物工程技术有限公司 一种依西美坦片及其制备方法
CN101863806B (zh) * 2010-03-18 2013-02-13 湖北省医药工业研究院有限公司 抗***癌药物(r)-比卡鲁胺的制备方法
WO2011146583A2 (en) * 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
JP5978424B2 (ja) * 2010-07-29 2016-08-24 国立大学法人京都大学 抗がん剤のスクリーニング方法
US20130261142A1 (en) * 2010-12-15 2013-10-03 Hung-Cheng Lai Compounds used for treating cancer and the use thereof
CN102631354B (zh) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 含维生素d3和二甲双胍的药物组合物
CN102688493B (zh) * 2011-03-25 2014-09-10 鼎泓国际投资（香港）有限公司 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用
CN102813643B (zh) * 2011-06-10 2014-09-24 北京蛋白质组研究中心 bumetanide在抑制肝癌细胞转移中的应用
EP2760473A1 (en) * 2011-09-27 2014-08-06 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
CN109985228A (zh) * 2011-11-10 2019-07-09 凯伊药品公司 拟钙剂及其使用方法
CN102600077B (zh) * 2012-03-29 2013-06-05 江苏豪森药业股份有限公司 吉西他滨或其盐纳米乳剂注射液及其制备方法
ES2384069B1 (es) * 2012-03-29 2013-07-04 Hospital Sant Joan De Déu Cinacalcet y tumores neuroblásticos
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014036654A1 (en) * 2012-09-06 2014-03-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
BR112015006176B1 (pt) * 2012-09-21 2023-04-18 Intensity Therapeutics, Inc Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular
CN103356687B (zh) * 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
CN105142631A (zh) * 2013-01-14 2015-12-09 健康诊所有限公司 抗癌药物和用途
CN103933569B (zh) * 2013-01-22 2017-01-11 复旦大学 一种抗肺癌药物组合物及其应用、药盒和包装件
EP2970145B1 (en) * 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
CN104161759B (zh) * 2013-05-16 2019-10-08 中国科学院上海药物研究所 阿那格雷及其衍生物的抗肿瘤用途
CN103396419A (zh) * 2013-08-13 2013-11-20 海宁市绿升医药科技有限公司 肿瘤光动力治疗药二氢卟吩e6-15-乙酯及其制备方法
CN103536925B (zh) * 2013-10-28 2015-07-01 中国医学科学院基础医学研究所 强心苷化合物在非小细胞肺癌治疗中的应用
CN103622975B (zh) * 2013-11-07 2016-06-15 广东药学院 格列吡嗪在制备***药物中的应用
KR20160143775A (ko) * 2014-04-08 2016-12-14 더 메서디스트 하스피틀 iNOS-억제 조성물들 및 이들의 유방암 치료제로서의 용도
AU2015335391B2 (en) * 2014-10-24 2018-06-21 Launx Biomedical Co., Ltd. Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024311A1 (en) * 2005-08-24 2007-03-01 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
WO2008085875A2 (en) * 2007-01-05 2008-07-17 Cornerstone Therapeutics Inc. R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma)
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
WO2012100248A1 (en) * 2011-01-23 2012-07-26 The University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
WO2014053650A1 (en) * 2012-10-04 2014-04-10 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DARAKHSHAN, S. ET AL.: "The Effects of Tamoxifen in Combination with Tranilast on CXCL12-CXCR4 Axis and Invasion in Breast Cancer Cell Lines", IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, vol. 13, no. 2, 28 February 2014 (2014-02-28), XP055274799, ISSN: 1726-6882 *
SHIGEMIZU, D. ET AL.: "Using Functional Signatures to Identify Repositioned Drugs for Breast, Myelogenous Leukemia and Prostate Cancer", PLOS COMPUTATIONAL BIOLOGY, vol. 8, no. 2, 29 February 2012 (2012-02-29), XP055080384, ISSN: 1553-7358 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
KR101933805B1 (ko) 2017-10-17 2018-12-28 성균관대학교산학협력단 옥셀라딘시트레이트를 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
TW201615220A (zh) 2016-05-01
TW201615195A (zh) 2016-05-01
TWI672150B (zh) 2019-09-21
TW201615197A (zh) 2016-05-01
WO2016062274A1 (zh) 2016-04-28
AU2015335375B2 (en) 2020-09-10
CN106999470A (zh) 2017-08-01
AU2015335375A1 (en) 2017-05-18
TWI663969B (zh) 2019-07-01
WO2016062290A1 (zh) 2016-04-28
WO2016062277A1 (zh) 2016-04-28
EP3235497A1 (en) 2017-10-25
WO2016062271A1 (zh) 2016-04-28
TW201615222A (zh) 2016-05-01
AU2015335391A1 (en) 2017-06-01
EP3210604C0 (en) 2024-02-14
US10045962B2 (en) 2018-08-14
CN107106550A (zh) 2017-08-29
ES2954860T3 (es) 2023-11-27
TW201615221A (zh) 2016-05-01
TW201615184A (zh) 2016-05-01
US20170216247A1 (en) 2017-08-03
TW201615191A (zh) 2016-05-01
WO2016062283A1 (zh) 2016-04-28
TWI652060B (zh) 2019-03-01
EP3222278A4 (en) 2018-06-20
EP3222278C0 (en) 2023-06-14
TW201615192A (zh) 2016-05-01
US20170304218A1 (en) 2017-10-26
JP2017532351A (ja) 2017-11-02
US20170304286A1 (en) 2017-10-26
EP3210604A1 (en) 2017-08-30
WO2016062289A1 (zh) 2016-04-28
AU2015335391B2 (en) 2018-06-21
TW201615193A (zh) 2016-05-01
EP3222278A1 (en) 2017-09-27
WO2016062267A1 (zh) 2016-04-28
EP3222278B1 (en) 2023-06-14
US20170312260A1 (en) 2017-11-02
WO2016062285A1 (zh) 2016-04-28
JP6539345B2 (ja) 2019-07-03
WO2016062278A1 (zh) 2016-04-28
WO2016062266A1 (zh) 2016-04-28
WO2016062286A1 (zh) 2016-04-28
EP3210604B1 (en) 2024-02-14
TWI663984B (zh) 2019-07-01
TW201615224A (zh) 2016-05-01
TW201615189A (zh) 2016-05-01
WO2016062281A1 (zh) 2016-04-28
KR20170084034A (ko) 2017-07-19
TW201615188A (zh) 2016-05-01
TW201615219A (zh) 2016-05-01
WO2016062269A1 (zh) 2016-04-28
TW201615194A (zh) 2016-05-01
US20170304387A1 (en) 2017-10-26
EP3210604A4 (en) 2018-06-27
KR102490334B1 (ko) 2023-01-18
US20170304388A1 (en) 2017-10-26
CN107106523A (zh) 2017-08-29
TW201615223A (zh) 2016-05-01
WO2016062265A1 (zh) 2016-04-28
TW201615217A (zh) 2016-05-01
TW201615226A (zh) 2016-05-01
WO2016062291A1 (zh) 2016-04-28
TW201615218A (zh) 2016-05-01
WO2016062287A1 (zh) 2016-04-28
WO2016062272A1 (zh) 2016-04-28
WO2016062279A1 (zh) 2016-04-28
US10098852B2 (en) 2018-10-16
WO2016062288A1 (zh) 2016-04-28
US10105357B2 (en) 2018-10-23
US20170304228A1 (en) 2017-10-26
TWI621434B (zh) 2018-04-21
EP3235497A4 (en) 2018-06-13
WO2016062275A1 (zh) 2016-04-28
TW201615186A (zh) 2016-05-01
TW201615196A (zh) 2016-05-01
TW201615225A (zh) 2016-05-01

Similar Documents

Publication Publication Date Title
WO2016062270A1 (zh) 呼吸***疾病用药用于制备抗癌医药组合物的用途
Bionorica Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis
KR101801864B1 (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
CN111214550A (zh) 药物在治疗或预防新型冠状病毒肺炎2019-nCoV中的新用途
US20130216574A1 (en) Kit providing multiple unmet therapeutic effects
CN105012487B (zh) 小儿鼻舒通滴鼻液
CN102100789B (zh) 一种治疗咽炎的中药组合物及其制备方法
CN103463538A (zh) 哮喘药
Ahmed et al. Prescribing and utilization trends of anti-asthmatic drugs amongst children in a Tertiary Care Hospital in Lahore, Pakistan
US11744841B2 (en) Use of trezastilbenoside in manufacture of product for treating and/or preventing disease of respiratory system
TWI720396B (zh) 片仔癀及其製劑在治療帶狀皰疹後遺神經痛中的用途
Kamin et al. Pinimenthol® ointment in patients suffering from upper respiratory tract infections–A post-marketing observational study
CN102716128A (zh) 一种治疗哮喘的药用组合物
Ismail et al. Colds and flu–an overview of the management
CN103961654B (zh) 一种白葡萄球菌片及其制备方法
CN104721573A (zh) 一种治疗痰湿型慢性支气管炎的中药组合物
Schmidt How to approach a cough–are you asking the right questions?
CN103006827A (zh) 一种治疗肺结核的闻药及其制备方法
CN114053278A (zh) 一种治疗咳嗽的复方制剂及制备方法
Ismail et al. Colds and flu–an overview of their management
Schmidt An OTC approach to managing cough
CN104352586A (zh) 青鹏软膏在制备治疗痔疮药物中的应用
CN117653637A (zh) 恩替卡韦的新用途
CN108619373A (zh) 贝桔止咳糖浆的新用途
CN114569611A (zh) 一种治疗咳嗽并保护消化道的复方制剂及制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15853060

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15853060

Country of ref document: EP

Kind code of ref document: A1